Company profile for Avalyn Pharma

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Avalyn is a biopharma company committed to developing improved therapies for the treatment of idiopathic pulmonary fibrosis (IPF) and other severe respiratory diseases. Our lead asset is inhaled pirfenidone (AP01) for the treatment of IPF. With offices in Seattle and San Diego, Avalyn's experienced clinical and inhaled product development team is rapidly advancing AP01 for the treatment of IPF and additional pipeline candidate...
Avalyn is a biopharma company committed to developing improved therapies for the treatment of idiopathic pulmonary fibrosis (IPF) and other severe respiratory diseases. Our lead asset is inhaled pirfenidone (AP01) for the treatment of IPF. With offices in Seattle and San Diego, Avalyn's experienced clinical and inhaled product development team is rapidly advancing AP01 for the treatment of IPF and additional pipeline candidates for IPF and other severe respiratory diseases.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
701 Pike Street Suite 1500 Seattle, WA 98101
Telephone
Telephone
Linkedin
Linkedin
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

DCAT Week

DCAT Week

Not Confirmed

envelop Contact Supplier

DCAT Week

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.globenewswire.com/news-release/2025/12/17/3206942/0/en/Avalyn-to-Present-at-the-44th-Annual-J-P-Morgan-Healthcare-Conference.html

GLOBENEWSWIRE
17 Dec 2025

https://www.globenewswire.com/news-release/2025/11/03/3179172/0/en/Avalyn-to-Participate-in-Multiple-Upcoming-Investor-Conferences-in-November.html

GLOBENEWSWIRE
03 Nov 2025

https://www.globenewswire.com/news-release/2025/10/21/3170115/0/en/Avalyn-Announces-Multiple-Presentations-at-the-Pulmonary-Fibrosis-Foundation-PFF-Summit-2025.html

GLOBENEWSWIRE
21 Oct 2025

https://www.globenewswire.com/news-release/2025/10/01/3159426/0/en/Avalyn-Appoints-Industry-Veterans-Jill-Denning-and-Kimberley-Cummings-to-Leadership.html

GLOBENEWSWIRE
01 Oct 2025

https://www.globenewswire.com/news-release/2025/09/15/3149935/0/en/Avalyn-to-Highlight-AURA-IPF-Phase-2-Clinical-Trial-Design-for-AP02-Inhaled-Nintedanib-at-the-European-Respiratory-Society-International-Congress-2025.html

GLOBENEWSWIRE
15 Sep 2025

https://www.globenewswire.com/news-release/2025/08/25/3138403/0/en/Avalyn-to-Participate-in-Multiple-Upcoming-Investor-Conferences-in-September.html

GLOBENEWSWIRE
25 Aug 2025

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty